Darifenacin

CLINICAL USE

Symptomatic treatment of urinary incontinence, frequency or urgency

DOSE IN NORMAL RENAL FUNCTION

7.5–15 mg once daily

PHARMACOKINETICS

Molecular weight :426.6 (507.5 as hydrobromide)

%Protein binding :98

%Excreted unchanged in urine : 3

Volume of distribution (L/kg) :163 litres

half-life – normal/ESRD (hrs) :13–19/Unchanged

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Unlikely to be dialysed. Dose as in normal renal function

HD :Unlikely to be dialysed. Dose as in normal renal function

HDF/high flux :Unlikely to be dialysed. Dose as in normal renal function

CAV/VVHD :Unlikely to be dialysed. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsAntifungals: concentration increased by ketoconazole – avoid concomitant useAntivirals: avoid concomitant use with amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavirCalcium-channel blockers: avoid concomitant use with verapamilCiclosporin: avoid concomitant use

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home